Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019

被引:487
作者
Cefalu, William T.
Berg, Erika Gebel
Saraco, Mindy
Petersen, Matthew P.
Uelmen, Sacha
Robinson, Shamera
机构
关键词
GLARGINE; 100; U/ML; PEPTIDE-1 RECEPTOR AGONIST; TO-TARGET TRIAL; ACCIDENTAL INTRAMUSCULAR INJECTION; ORAL ANTIHYPERGLYCEMIC DRUGS; TYPE-1 DIABETES IMPLICATIONS; PROTAMINE HAGEDORN INSULIN; GLUCOSE-LOWERING DRUGS; REGULAR HUMAN INSULIN; BASAL-BOLUS REGIMEN;
D O I
10.2337/dc19-S009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The American Diabetes Association (ADA) Standards of Medical Care in Diabetes includes ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
引用
收藏
页码:S90 / S102
页数:13
相关论文
共 85 条
[1]   A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients [J].
Abd El Aziz, Mirna S. ;
Kahle, Melanie ;
Meier, Juris J. ;
Nauck, Michael A. .
DIABETES OBESITY & METABOLISM, 2017, 19 (02) :216-227
[2]   Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study [J].
Akturk, Halis Kaan ;
Snell-Bergeon, Janet K. ;
Rewers, Amanda ;
Klaff, Leslie J. ;
Bode, Bruce W. ;
Peters, Anne L. ;
Bailey, Timothy S. ;
Garg, Satish K. .
DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 (10) :639-647
[3]  
Amer Diabet Assoc, 2006, DIABETES CARE, V29, P935
[4]  
[Anonymous], FDA REV ZYNQ TM SOT
[5]  
[Anonymous], MICR 2 0 INTR RED BO
[6]  
[Anonymous], 2015, FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood
[7]  
[Anonymous], 2018, DIABETOLOGIA, DOI DOI 10.1007/s00125-018-4729-5
[8]  
[Anonymous], CONTR MAN PAT TYP 2
[9]  
[Anonymous], NADAC NAT AV DRUG AC
[10]   Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study [J].
Aroda, Vanita R. ;
Edelstein, Sharon L. ;
Goldberg, Ronald B. ;
Knowler, William C. ;
Marcovina, Santica M. ;
Orchard, Trevor J. ;
Bray, George A. ;
Schade, David S. ;
Temprosa, Marinella G. ;
White, Neil H. ;
Crandall, Jill P. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (04) :1754-1761